Back to search results

Understanding Postural Orthostatic Tachycardia Syndrome (POTS)

This observational study aims to better understand Postural Orthostatic Tachycardia Syndrome (POTS) by looking at many different aspects of the condition. Researchers will use various diagnostic tests, including blood tests (for immune system and hormone levels), heart scans (cardiac MRI), skin biopsies, and tests to measure blood volume. The goal is to define different types of POTS, improve how it's diagnosed, and help develop new treatments. You may be able to join if you are 14 years or older, meet the criteria for POTS (like a sustained increase in heart rate when standing), and can follow study procedures. The study will look at your POTS characteristics over two weeks and track your natural history for one year. The current status of this study is unclear.

Study design
This is an observational study aiming to enroll 350 participants. It is not testing a new treatment but rather gathering information about POTS.
What's involved
You would undergo multimodal diagnostic testing, including blood work, autonomic function testing, skin biopsy, CO rebreathing, and patient surveys. These tests will be conducted over a period of two weeks, with follow-up for one year.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for one year to understand the natural history of POTS.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06292104

Phenotyping of Postural Orthostatic Tachycardia Syndrome (POTS)

Recruiting
Not specifiedAges 14+Observational
University of Texas Southwestern Medical Center
~350 participants
Updated 2026-07-17 on ClinicalTrials.gov
What's tested:multimodal diagnostic testing

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Phenotyping POTS
Measured over 2 weeks
+1 more outcome measured

Conditions

Postural Orthostatic Tachycardia Syndrome

Explore related trials

Postural Orthostatic Tachycardia Syndrome

NCT06292104

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • UT Southwestern Medical Center

    Dallas, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Steven Vernino, MD PhD · PRINCIPAL_INVESTIGATOR · University of Texas Southwestern Medical Center

Who to contact

Steve Hopkins
[email protected]
214-648-9275
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 14 years, able to provide informed consent (assent with parental consent for age \< 18) and comply with procedures
Meets consensus criteria for POTS: (1) sustained increase in heart rate ≥ 30 bpm above supine baseline within 10 min of quiet standing or upright tilt (≥ 40 bpm in individuals 12 to 19 years of age) OR sustained upright HR (heart rate) \>120 bpm, (2) absence of orthostatic hypotension, (3) symptoms with standing that improve with sitting or lying down, (4) resting supine heart rate \< 100 bpm, (5) orthostatic symptoms present for at least 6 months
Stable oral medication regimen for at least 14 days
Healthy women, age 18 - 30 years, able to provide informed consent and comply with study procedures
Does NOT meet consensus criteria for postural tachycardia syndrome
No symptoms of orthostatic intolerance or dysautonomia. No history of other major medical disorder
Resting supine heart rate \< 100 bpm

Exclusion

Use of amphetamine-type stimulants, diuretics, selective norepinephrine reuptake inhibitor, anticholinergic medications (including tricyclic antidepressant medications), fludrocortisone, desmopressin in past 14 days
Use of other autonomic drugs (adrenergic agents, pyridostigmine, droxidopa, triptans, ivabradine) in past 48 hours
Currently receiving IVIG (Intravenous immunoglobulin), subcutaneous IgG (Immunoglobulin G), or any investigational medication (in past year)
Infusion of iv fluids in past 7 days
History or evidence of another condition explaining symptoms or orthostatic tachycardia (e.g. structural heart disease, CSF (Cerebrospinal fluid) hypovolemia, or severe traumatic brain injury)

What this trial measures

  • Phenotyping POTS2 weeks

    Assignment of participant to a phenotypic group(s) based on analysis of multimodal data

  • Natural history1 year

    Patient reported functional and subjective change. Surveys including COMPASS31 (Composite Autonomic Symptom Score-31) on a score of 0-100. Higher scores indicate more severe autonomic symptoms